Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clec12a-directed car-nk cells
- Development stage
- Preclinical
- Lead developer
- Universitätsmedizin Mainz
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CLEC12A-directed CAR-NK cells are an experimental adoptive cell therapy consisting of natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) targeting C-type lectin domain family 12 member A (CLEC12A), also known as CLL-1. CLEC12A is a cell surface glycoprotein frequently overexpressed on acute myeloid leukemia (AML) blasts and leukemic stem cells while being absent from healthy hematopoietic stem cells, making it a promising immunotherapeutic target. These CAR-NK cells typically incorporate intracellular signaling domains such as 4-1BB and CD3ζ to drive potent cytotoxic activity upon antigen recognition. Preclinical research suggests that the efficacy of CLEC12A-directed CAR-NK cells can be significantly enhanced by pretreatment with menin inhibitors, which upregulate CLEC12A expression on NPM1-mutated and KMT2A-rearranged AML cells.
- Other names
- CLL-1-directed CAR-NK cellsCLL1-directed CAR-NK cellsCLL 1-directed CAR-NK cellsCLEC12A CAR-NK cellsCLEC-12A CAR-NK cellsCLEC 12A CAR-NK cellsC-type lectin domain family 12 member A-directed CAR-NK cells
02
Targets
CLEC12A
Beyond the preview
Go deeper on clec12a-directed car-nk cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clec12a-directed car-nk cells.